Skip to Main Content

The YODA ProjectThe YODA Project

    • Welcome
      • Policies
      • Development
      • Due Diligence Assessment
      • Data Use Agreement
      • Data Expiration
    • Project Leadership
    • Steering Committee
    • Roles & Responsibilities
      • Partnering with the YODA Project
        • Overview
        • Available Data
        • Data Release Pilot Project
      • Johnson & Johnson Consumer Inc. (a subsidiary of Kenvue, Inc.)
        • Overview
        • Systematic Reviews
        • Approved Data Requests
      • QMUL
      • SI-BONE
    • Publications & Presentations
    • Announcements & Media Coverage
    • Relevant Literature
      • YODA Project Steering Committee and Stakeholders Conference
      • University College London and YODA Project Joint Meeting on Facilitating Data Access to Non-Industry Funded Research
    • Community Data Sharing Resources
    • FAQs
    • Acknowledgements
    • Contact Us
      • How To
      • Conflict of Interest
      • Data Use Agreement Training
    • Data Request Review Process
    • Request CSR Summary
    • Approved Data Requests
  • Trials
  • My Dashboard
    • YODA Project Metrics
      • Submitted Requests to Use Johnson & Johnson Data
      • Details of Data Requests
      • Clinical Trial Inquiries and CSR Summary Requests
      • Trials Determined to be Unavailable
  • Log in

Other Drugs for Treatment of Tuberculosis

NCT00523926 – An Open-label Study to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of TMC207 in Treatment-naive Subjects With Sputum Smear Positive Pulmonary Tuberculosis.

Posted on March 27, 2020 by tsuperadmin -

NCT00910871 – A Phase II, Open-label Trial With TMC207 as Part of a Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Subjects With Sputum Smear-positive Pulmonary Infection With MDR-TB

Posted on May 15, 2015 by tsuperadmin -

NCT00449644 – A Phase II, Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Subjects With Newly Diagnosed Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

Posted on May 15, 2015 by tsuperadmin -

Side navigation

Site Map
Yale University logo
CORE - Center for outcomes, research, and evaluation Logo
  • Visit the YODA Project on Facebook
  • Visit the YODA Project on X

Accessibility at Yale

website designed by Gravity Switch